查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1973760

IgE過敏血液檢測市場：依檢測類型、技術、應用、最終用戶和通路分類－2026-2032年全球預測

IgE Allergy Blood Tests Market by Test Type, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年 IgE 過敏血液檢測市值為 331 億美元，預計到 2026 年將成長至 347.9 億美元，複合年成長率為 5.46%，到 ​​2032 年將達到 480.3 億美元。

主要市場統計數據
基準年 2025 331億美元
預計年份：2026年 347.9億美元
預測年份 2032 480.3億美元
複合年成長率 (%) 5.46%

權威概述了 IgE 過敏血液檢測如何重新定義醫療保健環境中的診斷途徑、檢查室工作流程和臨床決策。

IgE介導的過敏檢測融合了臨床需求和診斷技術創新，是準確識別引起陣發性和慢性過敏性疾病的致敏因素的基礎。臨床醫生擴大利用血液IgE檢測來補充病歷和皮膚試驗，尤其是在皮膚試驗禁忌或多過敏原檢測有助於明確診斷的情況下。隨著診療路徑向個體化方向發展，檢查室和照護現場相關人員正在調整工作流程，將成分分解診斷和傳統的特異性IgE檢測相結合，並著重於臨床效用和可重複性。

檢測方法和診斷技術的快速成熟如何推動新的臨床工作流程、檢查室自動化和以患者為中心的過敏管理模式。

IgE過敏診斷領域正經歷著一場變革，其驅動力來自於技術的成熟、臨床需求的提升以及對個人化患者管理日益重視的。組成分解診斷技術的進步使得多過敏原檢測成為可能，超越了單一過敏原的識別，能夠揭示分子層面的致敏模式。這使得更精準的風險分層和更有針對性的規避策略成為可能。同時，包括全自動化學冷光免疫檢測和高性能螢光酵素免疫分析法在內的檢測平台的改進，在提高檢查室通量的同時，也提升了分析的準確性。

我們將評估新貿易措施對整個檢測生態系統的診斷供應鏈、採購實踐和檢查室韌性的營運和策略影響。

美國2025年實施的新關稅措施，為診斷試劑生產商和檢查室採購商的採購趨勢和供應鏈策略帶來了顯著變化。由於零件和試劑高度依賴進口，進口壓力迫使生產商加快審查籌資策略，重新評估供應商契約，並在某些情況下加快區域供應商的認證。這些營運變化已波及下游診斷檢查室和醫療保健系統，促使他們重新評估採購週期、庫存緩衝以及試劑供應合約的柔軟性。

詳細的細分資訊揭示了測試類型、檢測技術、臨床應用、最終用戶環境和通路如何影響產品設計和採用。

對細分市場的深入分析揭示了每種檢測類型、技術、應用、最終用戶和分銷管道的不同需求促進因素和營運考慮。基於檢測類型的差異包括成分特異性診斷、特異性IgE和總IgE檢測。成分特異性診斷活動進一步細分為多過敏原檢測（旨在最佳化致敏譜分析的廣度）和單過敏原檢測（旨在解決特定的臨床問題）。特異性IgE檢測區分成人和兒童應用場景，因為兩者在檢體處理和結果解讀方面存在差異。總IgE檢測服務提供定性快速檢測和定量檢測兩種形式，後者能夠反映潛在的免疫狀態。這些檢測類型的差異直接影響檢查室工作流程、報告格式和臨床醫生培訓需求。

區域診斷趨勢表明，臨床實踐、法規環境和醫療保健基礎設施如何決定不同全球醫療保健系統中檢測方法的採用。

從區域觀點來看，臨床實踐、法規結構和醫療基礎設施相互作用，共同決定了IgE過敏診斷的推廣應用路徑。在美洲，完善的檢測網路和強大的專科轉診途徑促進了多成分過敏原診斷和高通量自動化平台的廣泛應用。同時，私營和公共保險公司在報銷談判中優先考慮臨床效用和診斷結果的清晰度。在歐洲、中東和非洲，不同的法規環境和多元化的醫療資金籌措模式要求採用靈活的分銷策略和基於本地的臨床檢驗。在這些市場，與當地檢測機構和學術機構的合作能夠加速臨床醫生對IgE診斷的接受度和實證醫學證據的累積。在亞太地區，醫院基礎設施的快速發展、診斷檢查室的擴建以及對兒童過敏治療日益成長的關注，為定量總IgE檢測法和特異性IgE檢測創造了有利條件。然而，當地的生產和監管因素往往會影響採購選擇。

競爭格局模式顯示平台差異化、策略合作和卓越的服務品質如何推動診斷技術的應用和臨床整合。

診斷公司之間的競爭主要集中在平台差異化、更廣泛的檢測組合以及旨在擴大臨床應用範圍的策略聯盟。優先考慮互操作系統和全面檢測項目的機構往往能夠與檢查室工作流程和臨床醫生決策過程深度整合。投資於檢測標準化、外部品質保證和臨床醫生解讀工具能夠增強人們對檢測結果的信心，並支持從過敏和免疫學到基層醫療等跨學科的臨床應用。

產業領導者應關注的實際策略重點包括：供應鏈韌性、與臨床醫生的合作、模組化產品設計以及數據驅動的價值證明。

產業領導者應尋求供應鏈韌性、臨床參與和產品多功能性之間的實質平衡，以保持競爭力並發揮臨床意義。他們應優先選擇關鍵試劑和組件的替代供應商，並盡可能探索區域性生產夥伴關係，以降低貿易引發的供應衝擊風險。同時，他們應透過投資平台模組化設計來維持檢查室客戶的服務連續性，從而降低營運風險，使耗材能夠在不影響分析完整性的前提下進行替換。

我們採用了一種嚴謹的混合調查方法，結合了對臨床相關人員的訪談、對測試平台的技術審查以及基於場景的供應鏈分析，以獲得可操作的見解。

本分析的研究基礎是將對臨床負責人、實驗室經理和採購專家的訪談與對同行評審的臨床文獻、監管指導文件以及公開的檢測平台技術規範的系統性回顧相結合。相關人員的定性意見體現在對臨床應用障礙、操作限制和採購決策標準的解釋。臨床發現和技術文件的交叉檢驗證實，關於檢測性能特徵和實施實際情況的觀察結果與臨床實踐和製造商規範均相符。

將診斷創新、操作要求和協作策略進行簡潔整合，以將 IgE 檢測的進步與改善患者照護聯繫起來。

總而言之，IgE過敏血液檢測的格局正在從分散的診斷方法轉向以技術驅動的整合方法，從而支持個人化過敏治療。可分解診斷技術和實驗室自動化的進步使臨床醫生能夠獲得更清晰的免疫學特徵，而檢查室和採購團隊則面臨著維持服務連續性和成本效益的營運壓力。貿易中斷進一步加劇了對具有韌性的籌資策略和靈活產品設計的迫切需求，而監管環境和醫療服務提供方面的區域差異也要求採取因地制宜的方法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依檢測類型分類的IgE過敏血液檢測市場

  • 按組件進行診斷
    • 多過敏原檢測
    • 單一過敏原
  • 特異性IgE
    • 成人版
    • 適合兒童
  • 總IgE
    • 定性
    • 定量

第9章：IgE過敏血液檢測市場：依技術分類

  • 化學冷光免疫檢測
    • 全自動
    • 半自動
  • 酵素免疫分析法
  • 螢光酵素免疫分析法

第10章：IgE過敏血液檢測市場：依應用領域分類

  • 藥物過敏
  • 食物過敏
  • 呼吸道過敏

第11章：IgE過敏血液檢測市場：以最終用戶分類

  • 診所
  • 診斷檢查室
  • 醫院
  • 研究機構

第12章：IgE過敏血液檢測市場：依通路分類

  • 直銷
  • 批發商
  • 線上銷售

第13章：IgE過敏血液檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 IgE過敏血液檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：IgE過敏血液檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國IgE過敏血液檢測市場

第17章：中國IgE過敏血液檢測市場

第18章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • Danaher Corporation
  • DST Diagnostische Systeme & Technologien GmbH
  • Eurofins Scientific SE
  • HYCOR Biomedical LLC
  • Laboratory Corporation of America Holdings
  • Omega Diagnostics Group PLC
  • Quest Diagnostics Incorporated
  • R-Biopharm AG
  • Roche Holdings, Inc.
  • Siemens Healthineers AG
  • Stallergenes Greer plc
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-546E6FBB35FC

The IgE Allergy Blood Tests Market was valued at USD 33.10 billion in 2025 and is projected to grow to USD 34.79 billion in 2026, with a CAGR of 5.46%, reaching USD 48.03 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.10 billion
Estimated Year [2026] USD 34.79 billion
Forecast Year [2032] USD 48.03 billion
CAGR (%) 5.46%

An authoritative overview of how IgE allergy blood testing is redefining diagnostic pathways, laboratory workflows, and clinical decision-making across care settings

IgE-mediated allergy testing sits at the intersection of clinical need and diagnostic innovation, serving as a cornerstone for precise identification of sensitizations that drive episodic and chronic allergic disease. Clinicians increasingly rely on blood-based IgE assessments to complement patient histories and skin testing, particularly when skin testing is contraindicated or when multi-allergen panels accelerate diagnostic clarity. As care pathways evolve toward greater personalization, laboratory and point-of-care stakeholders are adapting workflows to integrate both component resolved diagnostics and conventional specific IgE assays, with a focus on clinical utility and reproducibility.

Shifts in laboratory automation, assay sensitivity, and clinician demand are redefining how IgE testing is perceived within broader immunology and allergy management. Alongside these technical developments, payers and procurement teams are scrutinizing the value proposition of different test formats, balancing throughput, ease of interpretation, and the potential to reduce downstream clinical uncertainty. Consequently, organizations across healthcare delivery and diagnostics are reassessing investment priorities to ensure testing portfolios support both acute decision-making and long-term allergy management strategies.

How rapid technological maturation in assays and diagnostics is catalyzing new clinical workflows, laboratory automation, and patient-centered allergy management models

The landscape of IgE allergy diagnostics is undergoing transformative shifts driven by technological maturation, clinical expectation, and a heightened emphasis on personalized patient management. Advances in component resolved diagnostics have moved beyond single-allergen determination to offer multi-allergen panels that reveal molecular sensitization patterns, thereby enabling more nuanced risk stratification and targeted avoidance strategies. At the same time, improvements in assay platforms, including fully automated chemiluminescence immunoassays and high-performing fluorescence enzyme immunoassays, are increasing laboratory throughput while tightening analytical precision.

These technological advances are accompanied by evolving clinical workflows. Clinicians are integrating both specific IgE testing for adult and pediatric populations and total IgE measurements provided in qualitative and quantitative formats into diagnostic algorithms depending on clinical context. Moreover, the rise of integrated laboratory information systems and data analytics is facilitating longitudinal tracking of IgE profiles, which supports allergists and primary care physicians in monitoring disease progression and response to immunotherapies. Transitioning from traditional paradigms to these more integrated models requires coordinated change management across laboratories, clinicians, and procurement stakeholders to realize improved patient outcomes.

Assessing the operational and strategic ramifications of new trade measures on diagnostic supply chains, procurement behavior, and laboratory resiliency across the testing ecosystem

The introduction of new tariff measures in the United States during 2025 has introduced discernible shifts in procurement dynamics and supply chain strategies for diagnostic manufacturers and laboratory buyers. Import-dependent components and reagent imports have experienced cost pressures that compel manufacturers to revisit sourcing strategies, re-evaluate supplier contracts, and, in some instances, accelerate qualification of regional suppliers. These operational changes are filtering downstream to diagnostic laboratories and healthcare systems, prompting a reassessment of procurement windows, inventory buffers, and contractual flexibility in reagent supply commitments.

Beyond procurement and inventory tactics, the tariff environment has incentivized firms to explore local manufacturing partnerships and to prioritize modular assay designs that allow substitution of tariff-affected consumables. In parallel, distributors and channel partners have had to adapt pricing and logistics models to preserve service levels while managing margin compression. For clinicians and healthcare providers, the effect has been a heightened focus on test selection criteria that balance analytical performance with supply resiliency, urging greater collaboration between clinical decision-makers and laboratory procurement teams to ensure continuity of care despite evolving trade conditions.

Detailed segmentation intelligence revealing how test types, assay technologies, clinical applications, end-user environments, and distribution pathways shape product design and adoption

A nuanced view of segmentation reveals differentiated demand drivers and operational considerations across test types, technologies, applications, end users, and distribution channels. Based on test type, distinctions arise among component resolved diagnosis, specific IgE, and total IgE; component resolved diagnosis activity differentiates further between multi-allergen panel approaches that optimize breadth of sensitization profiling and single allergen assays that support focused clinical questions; specific IgE testing distinguishes adult and pediatric use cases with divergent specimen handling and interpretive needs; total IgE services are delivered in both qualitative rapid formats and quantitative assays that inform baseline immune status. These test-type distinctions directly influence laboratory workflows, reporting formats, and clinician education needs.

Based on technology, assay selection among chemiluminescence immunoassay, enzyme linked immunosorbent assay, and fluorescence enzyme immunoassay shapes automation potential and throughput. Within chemiluminescence immunoassays, the choice between fully automated and semi-automated platforms speaks to the trade-off between labor optimization and capital flexibility. Based on application, clinical demand is segmented into drug allergy, food allergy, and respiratory allergy, each creating specific test ordering patterns, interpretation complexity, and follow-up pathways. Based on end user, implementation realities differ across clinics, diagnostic laboratories, hospitals, and research institutes, with each setting bringing distinct quality control, staffing, and reporting requirements. Based on distribution channel, procurement and service models vary among direct sales relationships, distributor networks, and online sales platforms, affecting lead times, technical support availability, and pricing transparency. Taken together, these segmentation dimensions guide manufacturers and laboratory leaders in aligning product design, go-to-market models, and educational outreach to the precise needs of clinicians and institutional buyers.

Regional diagnostics dynamics showing how clinical practices, regulatory contexts, and healthcare infrastructure determine testing adoption across diverse global healthcare systems

Regional perspectives underscore that clinical practice, regulatory frameworks, and healthcare infrastructure converge to determine the adoption trajectory of IgE allergy diagnostics. In the Americas, established laboratory networks and strong specialist referral pathways support broad adoption of both multi-allergen component diagnosis and high-throughput automated platforms, while private and public payers emphasize clinical utility and diagnostic clarity in reimbursement conversations. In Europe, Middle East & Africa, diverse regulatory environments and heterogeneous healthcare funding models demand adaptable distribution strategies and localized clinical validation; in these markets, partnerships with regional laboratories and academic centers can accelerate clinician acceptance and evidence generation. In the Asia-Pacific region, rapid investment in hospital infrastructure, expanding diagnostic laboratories, and a growing emphasis on pediatric allergy care create fertile ground for both quantitative total IgE assays and specific IgE testing, though local manufacturing and regulatory considerations often influence procurement choices.

Across regions, the balance between centralized laboratory testing and near-patient solutions varies with healthcare delivery models and geographic access to specialist care. Consequently, manufacturers and clinical networks must calibrate training, technical support, and supply chain design to the realities of each region, ensuring that assay performance translates into actionable clinical insight regardless of local constraints.

Competitive landscape patterns illustrating how platform differentiation, strategic partnerships, and service excellence drive diagnostic adoption and clinical integration

Competitive behavior among diagnostic companies is centered on platform differentiation, assay portfolio breadth, and strategic partnerships that extend clinical reach. Organizations that prioritize interoperable systems and comprehensive panel offerings often gain deeper integration into laboratory workflows and clinician decision-support pathways. Investment in assay standardization, external quality assurance, and clinician-facing interpretive tools enhances confidence in test results and supports clinical adoption across specialties ranging from allergy and immunology to primary care.

Meanwhile, collaborations between diagnostics manufacturers and reagent suppliers, contract manufacturers, and academic centers are shaping the innovation pipeline. These alliances can shorten time-to-validation for new allergen components and support real-world evidence generation. Sales and distribution strategies are also evolving: direct sales relationships facilitate tailored implementation and training, whereas distributor networks and online channels expand reach into fragmented markets. Across the competitive landscape, the firms that combine robust analytical performance with practical service delivery and strong educational outreach are best positioned to support clinician needs and laboratory scalability.

Action-oriented strategic priorities for industry leaders focused on supply resilience, clinician engagement, modular product design, and data-driven value demonstration

Industry leaders should pursue a pragmatic combination of supply resilience, clinical engagement, and product versatility to remain competitive and clinically relevant. Prioritize qualification of alternative suppliers for critical reagents and components and explore regional manufacturing partnerships where feasible to reduce exposure to trade-driven supply shocks. Concurrently, invest in platform modularity that allows substitution of consumables without compromising analytical integrity, which preserves service continuity for laboratory clients and reduces operational risk.

Strengthening clinician engagement through targeted education on interpretive nuances of component resolved diagnostics and age-specific considerations for specific IgE testing will amplify clinical utility and appropriate test utilization. Additionally, align commercial models to the realities of end users by offering flexible service and training packages tailored to clinics, diagnostic laboratories, hospitals, and research institutes. Finally, enhance data capabilities to support longitudinal patient tracking and real-world evidence generation, enabling clearer demonstration of clinical impact to payers and institutional purchasers and supporting sustained integration into care pathways.

A rigorous mixed-methods research approach combining clinical stakeholder interviews, technical review of assay platforms, and scenario-based supply chain analysis to produce actionable insights

The research underpinning this analysis synthesizes primary interviews with clinical leaders, laboratory directors, and procurement specialists, together with a structured review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical specifications for assay platforms. Qualitative input from stakeholders informed interpretations of clinical adoption barriers, operational constraints, and procurement decision criteria. Cross-validation between clinical insights and technical documentation ensured that observations about assay performance characteristics and implementation realities are grounded in both real-world practice and manufacturer specifications.

Data collection emphasized transparency in source attribution and methodological rigor in synthesizing diverse evidence streams. The approach prioritized triangulation of stakeholder perspectives to mitigate single-source bias and incorporated pragmatic assessments of supply chain and regulatory drivers through scenario-based analysis. Where direct quantitative aggregation was inappropriate, the methodology focused on thematic synthesis to produce actionable insights that respect the complexity of clinical, laboratory, and commercial environments.

A concise synthesis of diagnostic innovation, operational imperatives, and collaborative strategies needed to translate IgE test advances into improved patient care

In sum, the IgE allergy blood testing landscape is moving from fragmented diagnostic practices toward more integrated, technology-enabled approaches that support personalized allergy care. Advances in component resolved diagnostics and assay automation are enabling clinicians to obtain clearer immunological profiles, while laboratories and procurement teams navigate operational pressures to maintain service continuity and cost-effectiveness. Trade-related disruptions have reinforced the need for resilient sourcing strategies and flexible product designs, and regional variations in regulatory and healthcare delivery contexts require tailored market approaches.

Looking ahead, stakeholders who align product development with clinical decision-making needs, invest in clinician education, and fortify supply chain flexibility will be best positioned to translate diagnostic innovation into improved patient management. Closing the gap between analytical capability and practical clinical implementation will rely on collaborative effort across manufacturers, laboratories, clinicians, and distributors to ensure testing reliably informs patient-centered care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IgE Allergy Blood Tests Market, by Test Type

  • 8.1. Component Resolved Diagnosis
    • 8.1.1. Multi Allergen Panel
    • 8.1.2. Single Allergen
  • 8.2. Specific Ige
    • 8.2.1. Adult
    • 8.2.2. Pediatric
  • 8.3. Total Ige
    • 8.3.1. Qualitative
    • 8.3.2. Quantitative

9. IgE Allergy Blood Tests Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
    • 9.1.1. Fully Automated
    • 9.1.2. Semi Automated
  • 9.2. Enzyme Linked Immunosorbent Assay
  • 9.3. Fluorescence Enzyme Immunoassay

10. IgE Allergy Blood Tests Market, by Application

  • 10.1. Drug Allergy
  • 10.2. Food Allergy
  • 10.3. Respiratory Allergy

11. IgE Allergy Blood Tests Market, by End User

  • 11.1. Clinics
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. IgE Allergy Blood Tests Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Online Sales

13. IgE Allergy Blood Tests Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. IgE Allergy Blood Tests Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. IgE Allergy Blood Tests Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States IgE Allergy Blood Tests Market

17. China IgE Allergy Blood Tests Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton, Dickinson and Company
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. Bio-Techne Corporation
  • 18.9. bioMerieux SA
  • 18.10. Danaher Corporation
  • 18.11. DST Diagnostische Systeme & Technologien GmbH
  • 18.12. Eurofins Scientific SE
  • 18.13. HYCOR Biomedical LLC
  • 18.14. Laboratory Corporation of America Holdings
  • 18.15. Omega Diagnostics Group PLC
  • 18.16. Quest Diagnostics Incorporated
  • 18.17. R-Biopharm AG
  • 18.18. Roche Holdings, Inc.
  • 18.19. Siemens Healthineers AG
  • 18.20. Stallergenes Greer plc
  • 18.21. Sysmex Corporation
  • 18.22. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IGE ALLERGY BLOOD TESTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY MULTI ALLERGEN PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY MULTI ALLERGEN PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY MULTI ALLERGEN PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SINGLE ALLERGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SINGLE ALLERGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SINGLE ALLERGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FULLY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FULLY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FULLY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SEMI AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SEMI AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SEMI AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FLUORESCENCE ENZYME IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FLUORESCENCE ENZYME IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FLUORESCENCE ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DRUG ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DRUG ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DRUG ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FOOD ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FOOD ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY FOOD ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESPIRATORY ALLERGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESPIRATORY ALLERGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESPIRATORY ALLERGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 178. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 208. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 218. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY COMPONENT RESOLVED DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY SPECIFIC IGE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TOTAL IGE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA IGE ALLERGY BLOOD TESTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)